Products & Services · Percent Change (as a percent)
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — Percent Change (as a percent)
Johnson & Johnson PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — Percent Change (as a percent) increased by 186.2% to 10.0% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 370.3%, from -3.7% to 10.0%. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2018
Last reportedQ1 2026Apr 22, 2026
How to read this metric
Positive growth indicates successful market retention or expansion, whereas negative growth suggests potential market share erosion or the impact of patent expirations.
Detailed definition
This metric measures the period-over-period growth rate of revenue derived from a specific portfolio of HIV antiviral me...
Peer comparison
Comparable to year-over-year or quarter-over-quarter revenue growth rates reported for specific drug portfolios by peer pharmaceutical firms.
Metric ID:
jnj_segment_prezista_prezcobix_rezolsta_symtuza_percent_change_as_a_percentHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -1% | -1.7% | -1.7% | -8.3% | -7.9% | -6.4% | -4.8% | 5.8% | -7.8% | -2.2% | -12.3% | -11% | 0.6% | -3.7% | -9.4% | -11.6% | 10% |
| QoQ Change | — | -70.0% | +0.0% | -388.2% | +4.8% | +19.0% | +25.0% | +220.8% | -234.5% | +71.8% | -459.1% | +10.6% | +105.5% | -716.7% | -154.1% | -23.4% | +186.2% |
| YoY Change | — | — | — | — | -690.0% | -276.5% | +42.2% | +173.4% | -21.9% | — | -156.3% | -289.7% | +107.7% | +69.9% | +14.5% | <-999% | +370.3% |
Range-12.3% – 10%
CAGR+77.8%
Avg YoY Growth-224.1%
Median YoY Growth-3.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — percent change (as a percent)?
- Johnson & Johnson (JNJ) reported prezista/prezcobix/rezolsta/symtuza — percent change (as a percent) of 10.0% in Q1 2026.
- How has Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — percent change (as a percent) changed year-over-year?
- Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — percent change (as a percent) increased by 370.3% year-over-year, from -3.7% to 10.0%.
- What does prezista/prezcobix/rezolsta/symtuza — percent change (as a percent) mean?
- The percentage growth or decline in revenue for a specific group of HIV medications compared to a prior period.